

What is claimed is:

1. At least one of the following peptides or their effective parts with hormonal or hormone-like function and/or cytokine-like function selected from the group consisting of

(1₁) KPKAA KPKAA KPKAA KPKKA APKKK
(1₂) KPKAA KARVT KPKTA KPKKA APKKK
(1₃) AAKAV KPKAA KPKVV KPKKA APKKK
(1₄) KPKAA KPKSG KPKVT KAKKA APKKK
(1₅) KPKAA KPKTA KPKAA KPKAA AAKKK
(1₆) KPKAA KPKAA KPKAA KAKKA AAKKK
(1₇) KPKAA KPKAA KPKAA KP KAKKA AAKKA
(2) PEPAK SAPAP KKGSK KAVTK AQKKD GKRRK
RSEKE, and
(3) SYSVY VYKVL KQVHP DTGIS SKAMG IMNSF
VNDIF ERIAGE

is used in the diagnosis and/or therapy of autoimmune diseases, in particular diseases of the rheumatic group as systemic lupus erythematosus, rheumatoid arthritis or systemic sclerosis.

2. Effective part of a peptide (11 to 17) according to claim 1 containing at least eight amino acids and/or including at least one consensus sequence depicted as boxes of five amino acids whereby the C terminal is always A x K K K (x = A or P).
3. A method for improving diagnosis of autoimmune diseases, in particular diseases of the rheumatic group as systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosis comprising a first step, wherein a

09884E-4404

administering to a patient a pharmaceutical composition comprising a therapeutically active amount of at least two peptides or their effective parts according to claim 1.

9. A method according to claim 8, wherein said pharmaceutical composition is an injectable solution and is administered by an injection.
10. A method for the production of the antiidiotypic antibody, which specifically binds to the antigen-binding site of a monoclonal antibody, said monoclonal antibody specifically binding both a peptide or its effective part having an amino acid sequence selected from the group consisting of (1₁) to (1₇) of claim 1 and to a peptide or its effective part (2), comprising at least one step of a selection for a hybridoma clone, wherein said monoclonal antibody is used as an antigen.
11. A method for improving the diagnosis of an autoimmune disease, in particular diseases of the rheumatic group as systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosis, comprising a step, wherein a tissue sample taken from the body of a patient is brought into contact with an antiidiotypic antibody according to claim 9 and specific binding of an antibody comprised in said tissue sample to said antiidiotypic antibody is detected to receive an antiidiotypic antibody which has specifically bound to an antibody.
12. A method according to claim 11, wherein said tissue sample is a serum sample, a blood sample, a sputum sample, a liquor sample, a urine sample or a tear sample.
13. A method for therapy of autoimmune diseases, in particular diseases of the rheumatic group as systemic lupus erythematosus (SLE), rheumatoid arthritis or systemic sclerosis comprising administering to a patient a pharmaceutical composition comprising a therapeutically active amount of an antiidiotypic antibody according to claim 9.

0000159 1101

14. A method according to claim 13, wherein said pharmaceutical composition is an injectable solution and is administered by an injection.

TOPT 8978860